GMED
Globus Medical Inc. · NYSE
$70.54+0.46 (+0.66%)today
Globus Medical Inc. (GMED) is a Medical/Dental Instruments company listed on NYSE. In the last 30 days Quantisnow tracked 9 wire items for GMED, including 3 SEC filings, 2 insider trades and 1 M&A update. The most recent was published Nov 12, 2026.
GMED rankings
Price$70.54+0.46 (+0.66%)
02:30 PM08:45 PM
Financial highlights
Full financials- Revenue, TTM
- $3.14B
- Revenue growth
- +13.4%
- Net income, TTM
- $557.64M
- Net margin
- 17.8%
- Free cash flow, TTM
- $766.55M
- Cash
- $441.27M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Hiring
Nov 19, 2026Globus Medical Inc. lists 318 open roles on its careers site as of Nov 19, 2026, the most in Operations (79).
- Open roles
- 318
By team
- Operations79
- Research & Development70
- General Sales65
- Clinical Services25
- Information Technology19
- Product Marketing (Old) (Inactive)12
By location
- Audubon, PA127
- Pennsylvania - Limerick32
- Methuen, MA16
- Ohio8
- Illinois7
- Memphis, TN7
Counted daily from Globus Medical Inc.'s careers site.
News · 26 weeks27+800%
2026-05-242026-11-15
Mix1490d
- SEC Filings4(29%)
- Insider3(21%)
- M&A2(14%)
- Other2(14%)
- Earnings2(14%)
- Analyst1(7%)
Activity · 52 weeks6741 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Tobin James R exercised 41,666 shares at a strike of $56.30 and sold $3,131,547 worth of shares (41,666 units at $75.16) (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- SECSEC Form 144 filed by Globus Medical Inc.144 - GLOBUS MEDICAL INC (0001237831) (Subject)
- PRGlobus Medical to Participate in Jefferies Global Healthcare ConferenceAUDUBON, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Jefferies Global Healthcare Conference in London. Management is scheduled to present on Wednesday, November 18, 2026, from 11:30-11:55 GMT. Interested parties can access the live and archived webcast of the presentation in the "News & Events", "Events & Webcasts" section of the Globus Medical investor relations website at https://www.investors.globusmedical.com/news-events/events-webcasts. About Globus Medical, Inc. Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal techn
- ANALYSTGlobus Medical downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Globus Medical from Outperform to Market Perform and set a new price target of $78.00
- INSIDERDirector Rhoads Ann D sold $425,000 worth of shares (5,000 units at $85.00) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 35,384 units (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- SECSEC Form 10-Q filed by Globus Medical Inc.10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
- SECGlobus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
- PRGlobus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase ProgramAUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Results Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis.Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported.GAAP net income for the quarter was $141.2 million.GAAP diluted earnings per share ("EPS") was $1.04, an increase of 18.2%. Non-GAAP diluted EPS was $1.23, an increase of 4.4%.GAAP gross profit as a percentage of net sales was 66.7%
- PRGlobus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial NeurosurgeryAUDUBON, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. a leading musculoskeletal technology company, today announced that it completed the acquisition of Synaptive Medical, deepening the Company's presence in cranial neurosurgery and positioning it for further growth in this market. Synaptive Medical is a medical technology company focused on developing solutions for complex cranial procedures, with technologies spanning surgical visualization, navigation, surgical planning, and MRI. The acquisition completed on August 4, 2026, through a court-appointed receivership process, adds to Globus Medical's portfolio of enabling technologies for neurosurgery. "This acquisition buil
- PRGlobus Medical Schedules Third Quarter Earnings Release and Conference CallAUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2026 after the market close on Thursday, November 5, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events
- INSIDERDirector Tobin James R exercised 30,000 shares at a strike of $58.72 and sold $2,237,502 worth of shares (30,000 units at $74.58) (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- SECSEC Form 144 filed by Globus Medical Inc.144 - GLOBUS MEDICAL INC (0001237831) (Subject)
- PRGlobus Medical Announces CE Mark for Excelsius3D™ Imaging SystemAUDUBON, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that the Excelsius3D™ intelligent 3-in-1 imaging system is now CE marked for commercial sale in the European Union and the United Kingdom. The addition of Excelsius3D™ expands the company’s Excelsius™ Ecosystem of enabling technologies and further enhances the capabilities of the ExcelsiusGPS™ robotic navigation system in the European Union. Excelsius3D™ is an intelligent, mobile imaging platform that combines 3D cone-beam computed tomography (CT), 2D fluoroscopy, and digital radiography in a single system. Designed for intraoperative use, Excels
- PRGlobus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital SolutionsAUDUBON, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and incubated out of Duke University. With a mission to transform healthcare experience through digital innovation, Higgs Boson will position Globus Medical to shape patient and provider experience throughout the full episode of care. "Higgs Boson employs highly experienced teams of software developers and AI scientists who will be joining our team to power our vision of a seamless digital healthcare environment to simplify a patient’s journey throug
- INSIDERDirector Zarrilli Stephen T exercised 25,000 shares at a strike of $53.27 and sold $2,175,965 worth of shares (25,000 units at $87.04) (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- SECSEC Form 144 filed by Globus Medical Inc.144 - GLOBUS MEDICAL INC (0001237831) (Subject)
- SECSEC Form 10-Q filed by Globus Medical Inc.10-Q - GLOBUS MEDICAL INC (0001237831) (Filer)
- SECGlobus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GLOBUS MEDICAL INC (0001237831) (Filer)
- PRGlobus Medical Reports Second Quarter 2026 ResultsAUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase of 5.9%, or an increase of 5.6% on a constant currency basis.GAAP net income for the quarter was $151.6 million.GAAP diluted earnings per share ("EPS") was $1.10, a decrease of 26.2%, primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. Non-GAAP diluted EPS was $1.34, an increase of 55.8%. "Momentum continued into the second qu
- INSIDERDirector Davidar David D gifted 2,500 shares, decreasing direct ownership by 0.49% to 507,675 units (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- ANALYSTUBS initiated coverage on Globus Medical with a new price targetUBS initiated coverage of Globus Medical with a rating of Neutral and set a new price target of $82.00
- PRGlobus Medical Schedules Second Quarter Earnings Release and Conference CallAUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webca
- ANALYSTBMO Capital Markets initiated coverage on Globus Medical with a new price targetBMO Capital Markets initiated coverage of Globus Medical with a rating of Outperform and set a new price target of $94.00
- INSIDERDirector Davidar David D exercised 25,000 shares at a strike of $26.27 and sold $2,019,072 worth of shares (25,000 units at $80.76) (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
- INSIDERDirector Rhoads Ann D exercised 25,000 shares at a strike of $26.27, increasing direct ownership by 163% to 40,384 units (SEC Form 4)4 - GLOBUS MEDICAL INC (0001237831) (Issuer)
GMED FAQ
12 questionsWhat does Globus Medical Inc. do?
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral...What is the latest news on GMED?
In the last 30 days Quantisnow tracked 9 wire items for GMED: 3 SEC filings, 2 insider trades, 1 M&A update and 1 earnings update. The most recent was published on November 12, 2026.What is GMED revenue?
Globus Medical Inc. (GMED) reported $3.14B of revenue for the twelve months ended Sep 30, 2026. That is up 13.4% from the year before. Revenue for fiscal 2025 was $2.94B.Is GMED profitable?
Yes. Globus Medical Inc. earned $557.64M in net income for the twelve months ended Sep 30, 2026, a net margin of 17.8%.How much cash and debt does GMED have?
Globus Medical Inc. reported $441.27M in cash and cash equivalents on its most recent balance sheet in SEC filings.Is Globus Medical Inc. (GMED) hiring?
Globus Medical Inc. lists 318 open roles on its careers site as of Nov 19, 2026, the most in Operations (79). The most openings are in Audubon, PA, Pennsylvania - Limerick and Methuen, MA.Where does GMED stock trade?
Globus Medical Inc. (GMED) is listed on NYSE.What sector and industry is GMED in?
Globus Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Globus Medical Inc. go public?
Globus Medical Inc. (GMED) completed its IPO in 2012.What are analysts saying about GMED?
Across the last 8 analyst actions on Globus Medical Inc., there were 3 upgrades and 1 downgrade. The most recent action was from BMO Capital Markets: Market Perform with a $78.00 price target on 2026-11-06. Recent price targets range from $64.00 to $112.00.What companies are similar to GMED?
Notable peers in the same industry include ZBH (Zimmer Biomet Holdings Inc.), MDT (Medtronic plc.), OFIX (Orthofix Medical Inc.), SYK (Stryker Corporation), ATEC (Alphatec Holdings Inc.). Compare GMED side-by-side with any of them on Quantisnow.How can I track GMED on Quantisnow?
Quantisnow aggregates Globus Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMED to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change